Search results for "PREVENTS"
showing 3 items of 3 documents
Inhibition of colon cancer growth by docosahexaenoic acid involves autocrine production of TNFα
2016
IF 7.932; International audience; The omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) has anti-inflammatory and anti-cancer properties. Among pro-inflammatory mediators, tumor necrosis factor a (TNF alpha) plays a paradoxical role in cancer biology with induction of cancer cell death or survival depending on the cellular context. The objective of the study was to evaluate the role of TNFa in DHA-mediated tumor growth inhibition and colon cancer cell death. The treatment of human colorectal cancer cells, HCT-116 and HCT-8 cells, with DHA triggered apoptosis in autocrine TNF alpha-dependent manner. We demonstrated that DHA-induced increased content of TNF alpha mRNA occurred thr…
El nuevo escenario del orden público en el arbitraje : comentario a la STC de España, Sala Primera, núm. 17/2021, de 15 de febrero.
2021
The Constitutional Court delimits the concept and scope of public order, the requirement to state the grounds and the judicial review within the framework of the action for annulment of arbitral awards. The Constitutional Court rejects the jurisprudential line of the High Court of Justice of Madrid regarding the broadening of the concept of public policy and prevents the review of the merits of the case through the action for annulment.
Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy
2017
Background: Inhibition of activin/myostatin pathway has emerged as a novel approach to increase muscle mass and bone strength. Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that leads to progressive muscle degeneration and also high incidence of fractures. The aim of our study was to test whether inhibition of activin receptor IIB ligands with or without exercise could improve bone strength in the mdx mouse model for DMD. Methods: Thirty-two mdx mice were divided to running and non-running groups and to receive either PBS control or soluble activin type IIB-receptor (ActRIIB-Fc) once weekly for 7 weeks. Results: Treatment of mdx mice with ActRIIB-Fc resulted in significantly…